Difference between revisions of "Semuloparin (AVE-5026)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 4: Line 4:
 
Route: SC
 
Route: SC
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
−
 
−
==Clinical trials==
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00694382 Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)]<ref name="SAVE-ONCO"></ref>
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00709904 Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery (SAVE-HIP3)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT01567904 Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00721760 Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery (SAVE-HIP2)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00679588 Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery (SAVE-ABDO)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00718224 Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery (SAVE-KNEE)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00697099 Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery (SAVE-HIP1)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00714597 Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility (SAVE-VEMED)]
 
−
*[http://clinicaltrials.gov/ct2/show/NCT00331838 Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery (TREK)]
 
  
 
==Patient drug information==
 
==Patient drug information==
Line 28: Line 17:
 
[[Category:Anticoagulants]]
 
[[Category:Anticoagulants]]
 
[[Category:Heparins]]
 
[[Category:Heparins]]
−
[[Category:Low molecular weight heparins]]
+
[[Category:Ultralow molecular weight heparins]]
  
 
[[Category:Investigational]]
 
[[Category:Investigational]]

Revision as of 15:56, 9 January 2018

General information

Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1][2]

Route: SC
Extravasation: n/a

Patient drug information

No information available.

References

  1. ↑ Semuloparin (AVE5026) manufacturer's website
  2. ↑ Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Semuloparin_(AVE-5026)&oldid=22269"